---
schema_version: "secwatch.filing_event.v1"
accession: "0001872789-22-000013"
form_type: "8-K"
ticker: "EMBC"
cik: "0001872789"
company_name: "Embecta Corp."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-24T00:06:45.581695+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Embecta Q3 revenue $291.1M, net income $62.4M; raises H2 FY2022 margin guidance

## Summary
- Revenue $291.1M (-1.3% reported, +2.0% constant currency); US +4.1%, international -7.1%.
- Net income $62.4M ($1.07 diluted EPS) vs $104.7M prior year; adjusted EBITDA margin 40.5% vs 48.7%.
- Declared $0.15/share quarterly dividend, payable Sept. 14 to holders of record Aug. 26.
- Raised H2 FY2022 adjusted gross margin guidance to mid-60%s (from low-60%s) and adjusted EBITDA margin to mid-30%s (from low-30%s); maintained revenue ~$555M.
- Developing type 2 closed-loop insulin patch pump with FDA Breakthrough Device Designation.

## SEC filing metadata
- accession: 0001872789-22-000013
- form_type: 8-K
- ticker: EMBC
- cik: 0001872789
- company_name: Embecta Corp.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1872789/000187278922000013/0001872789-22-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1872789/000187278922000013/embc-20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001872789-22-000013
- JSON: https://secwatch.observer/filing/0001872789-22-000013.json
- Plain text: https://secwatch.observer/filing/0001872789-22-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.